COMMUNIQUÉS West-GlobeNewswire

Sharps Technology Becomes SkyAI, Inc. with New Ticker Symbol “SKYA”; Establishing Category-defining Agentic Finance Platform Serving Global South
27/05/2026
Rebrand to SkyAI, Inc. to reflect evolution of the business to build a global agentic finance platform Opened operational headquarters in Hong Kong, a global hub for financial technology innovation and a base for [...]
Korro to Present at the 2026 Jefferies Global Healthcare Conference
27/05/2026
CAMBRIDGE, Mass., May 27, 2026 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO), a biopharmaceutical company leveraging a novel Oligonucleotide Promoted Editing of RNA (OPERA ® ) platform to develop a new [...]
LeonaBio to Participate in Upcoming Medical and Industry Meetings in June
27/05/2026
BOTHELL, Wash., May 27, 2026 (GLOBE NEWSWIRE) -- LeonaBio, Inc. (NASDAQ: LONA), a clinical-stage biopharmaceutical company dedicated to the development of novel therapeutics for diseases with high unmet medical needs, [...]
NRx Pharmaceuticals (Nasdaq: NRXP) Subsidiary HOPE Therapeutics Becomes First Commercial Site to Deploy Zeta Surgical's FDA-Cleared Zeta TMS Navigation System
27/05/2026
Deployment at HOPE's West Palm Beach clinic brings AI-powered, sub-millimetric image guidance to the delivery of Transcranial Magnetic Stimulation (TMS) for patients with Major Depressive Disorder and other neurological [...]
Maze Therapeutics to Participate in Two Upcoming Investor Conferences
27/05/2026
SOUTH SAN FRANCISCO, Calif., May 27, 2026 (GLOBE NEWSWIRE) -- Maze Therapeutics, Inc. (Nasdaq: MAZE), a clinical-stage biopharmaceutical company developing small molecule precision medicines for patients with kidney and [...]
MitoRx Therapeutics to present new preclinical data on MTRX31, its novel mitochondrial-targeted small molecule at the American Diabetes Association’s 2026 Scientific Sessions
27/05/2026
Poster to be presented at ADA 2026 on weight loss induced by MTRX31 in an industry-standard preclinical model of obesity MitoRx Chief Scientific Officer Xavier Jacq to also participate in panel and deliver corporate [...]
Apogee Therapeutics Announces $1.3 Billion Strategic Financing Collaboration with Blackstone Life Sciences to Advance Phase 3 Development and Commercialization of Zumilokibart
27/05/2026
Up to $1.3 billion in flexible, non-dilutive capital, including up to $800 million of synthetic royalty and access of up to $500 million in senior corporate debt Combined with company's current total cash of $1.3 [...]
TG Therapeutics Announces Positive Topline Results from Phase 3 ENHANCE Trial
27/05/2026
Phase 3 trial met its primary endpoint, demonstrating bioequivalent drug exposure between the currently approved BRIUMVI Day 1 and Day 15 initiation dosing and a new single infusion on Day 1 only Safety and tolerability [...]
BridgeBio Announces FDA Acceptance and Priority Review of NDA for BBP-418 for LGMD2I/R9
27/05/2026
- Accepted for Priority Review with PDUFA target action date of November 27, 2026, and poised to launch upon approval; being granted Priority Review by the FDA reiterates the serious unmet need for treatment options for [...]
Kymera Therapeutics to Participate in Fireside Chat at the Jefferies Global Healthcare Conference
27/05/2026
WATERTOWN, Mass., May 27, 2026 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological [...]
BioCryst to Present New HAE Data from ORLADEYO® (berotralstat) and Navenibart at the 2026 European Academy of Allergy and Clinical Immunology Annual Meeting
27/05/2026
RESEARCH TRIANGLE PARK, N.C., May 27, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will present seven abstracts from its hereditary angioedema (HAE) portfolio [...]
Reprogram Biosciences Closes Seed Financing to Advance Tumor Cell Reprogramming Therapeutics
27/05/2026
Company has now raised $6 million since founding to advance mRNA-based therapeutics designed to turn tumor cells into immune-activating cells SAN CARLOS, Calif., May 27, 2026 (GLOBE NEWSWIRE) -- Reprogram Biosciences, a [...]
HNL Lab Medicine Receives Accreditation from the College of American Pathologists
27/05/2026
ALLENTOWN, Pa., May 27, 2026 (GLOBE NEWSWIRE) -- HNL Lab Medicine has been awarded accreditation by the Accreditation Committee of the College of American Pathologists (CAP) following a recent on-site inspection [...]
Palvella Therapeutics Strengthens QTORIN™ Pitavastatin Intellectual Property with Yale-Licensed U.S. Patent Providing Protection into 2043
27/05/2026
Yale-licensed U.S. patent provides broad protection for topical mevalonate pathway inhibition in porokeratosis, including disseminated superficial actinic porokeratosis (DSAP) DSAP is a serious, rare, premalignant [...]
Intravacc obtient l’agrément CIR en France pour accompagner ses partenariats en R&D vaccinale
27/05/2026
Valable pour la période 2025–2027, cet agrément permet aux entreprises innovantes françaises de faire appel à l’expertise d’Intravacc dans le développement de vaccins, le développement analytique et la fabrication [...]
Zealand Pharma to Present Data at the American Diabetes Association's 2026 Scientific Sessions
27/05/2026
Press release – No. 10 / 2026 Zealand Pharma to Present Data at the American Diabetes Association's 2026 Scientific Sessions Late-breaking Phase 2 ZUPREME-1 data on petrelintide to be featured as ePoster Theater [...]
Intravacc Secures French CIR Approval to Support Vaccine R&D Partnerships
27/05/2026
The 2025-2027 approval helps French innovators access Intravacc’s vaccine development, analytical development and cGMP manufacturing services French Ministry approval recognizes Intravacc as a private research [...]
Bonito Biosciences and DaltonTx Announce AI-Driven Collaboration to Advance Precision Delivery for Oligotherapeutics
27/05/2026
Collaboration combines Bonito’s proprietary functional delivery data engine and ligand discovery platform with Dalton Tx ’s adaptive AI technology to accelerate precision oligotherapeutic delivery, beginning in the CNS [...]
Aligos Therapeutics Presents Positive Data at the EASL Congress 2026
27/05/2026
Long-term follow up data from the Phase 1 study of pevifoscorvir sodium continues to suggest a reduction in the cccDNA reservoir Data on the preclinical characteristics of the Aligos/Amoytop ASO program to be presented [...]

Pages